EP 1658859 A1 20060524 - APO-2L receptor agonist and CPT-11 synergism
Title (en)
APO-2L receptor agonist and CPT-11 synergism
Title (de)
APO-2L Rezeptor-Agonist und CPT-11 Synergie-Effekt
Title (fr)
Synergie des agonistes du récepteur APO-2L et du CPT-11
Publication
Application
Priority
- EP 00941233 A 20000607
- US 13824099 P 19990609
Abstract (en)
Methods of using synergistically effective amounts of Apo-2L receptor agonists and CPT-11 to induce apoptosis and suppress growth of cancer cell are provided.
IPC 8 full level
A61K 39/395 (2006.01); A61K 31/47 (2006.01); C07K 16/28 (2006.01)
CPC (source: EP)
A61K 39/39541 (2013.01); C07K 16/2878 (2013.01); A61K 2039/505 (2013.01); C07K 2317/73 (2013.01)
C-Set (source: EP)
Citation (applicant)
SCHOLTISSEK ET AL., GENE, vol. 62, 1988, pages 55 - 64
Citation (search report)
- [AD] WO 9725428 A1 19970717 - GENENTECH INC [US]
- [PA] WO 9937684 A1 19990729 - GENENTECH INC [US]
- [A] SCHILLER, JOAN H.: "Topotecan in small-cell lung cancer", SEMIN. ONCOL. (1997), 24(6, SUPPL. 20), S20/27-S20/33, 1997, XP000973356
- [AD] PAN, GUOHUA ET AL: "The receptor for the cytotoxic ligand TRAIL", SCIENCE (WASHINGTON, D. C.) (1997), 276(5309), 111 - 113, 1997, XP002158405
- [PA] ASHKENAZI A ET AL: "Safety and antitumor activity of recombinant soluble Apo2 ligand.", JOURNAL OF CLINICAL INVESTIGATION, (1999 JUL) 104 (2) 155-62., 1999, XP000973369
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
DOCDB simple family (application)
EP 06003358 A 20000607